Cargando…

Immunotherapy beyond progression in patients with advanced non-small cell lung cancer

BACKGROUND: Immune checkpoint inhibitors (ICIs) represent a great breakthrough in the treatment of advanced non-small cell lung cancer (aNSCLC). However, whether immunotherapy beyond progression (IBP) is effective for aNSCLC has yet to be established. Therefore, a retrospective clinical study was co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ge, Xiangwei, Zhang, Zhibo, Zhang, Sujie, Yuan, Fang, Zhang, Fan, Yan, Xiang, Han, Xiao, Ma, Junxun, Wang, Lijie, Tao, Haitao, Li, Xiaoyan, Zhi, Xiaoyu, Huang, Zhiyue, Hofman, Paul, Prelaj, Arsela, Banna, Giuseppe Luigi, Mutti, Luciano, Hu, Yi, Wang, Jinliang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815351/ https://www.ncbi.nlm.nih.gov/pubmed/33489801 http://dx.doi.org/10.21037/tlcr-20-1252

Ejemplares similares

Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
por: Zhang, Zhibo, et al.
Publicado: (2020)

Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
por: Zhang, Zhibo, et al.
Publicado: (2020)

First‐line PD‐1/PD‐L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non‐squamous non‐small cell lung cancer: A Bayesian network meta‐analysis of randomized controlled trials
por: Zhai, Jinzhao, et al.
Publicado: (2022)

Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors
por: Chen, Shixue, et al.
Publicado: (2020)

Clinical observation of immune checkpoint inhibitors in the treatment of advanced pancreatic cancer: a real-world study in Chinese cohort
por: Sun, Danyang, et al.
Publicado: (2018)

Prognostic value of baseline and change in neutrophil-to-lymphocyte ratio for survival in advanced non-small cell lung cancer patients with poor performance status receiving PD-1 inhibitors
por: Chen, Shixue, et al.
Publicado: (2021)

Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations
por: Ferrara, Roberto, et al.
Publicado: (2021)

Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis
por: Chen, Shixue, et al.
Publicado: (2021)

Decreased expression of RASSF10 correlates with poor prognosis in patients with colorectal cancer
por: Ma, Junxun, et al.
Publicado: (2017)

Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression
por: Prelaj, Arsela, et al.
Publicado: (2021)

Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer
por: Cui, Pengfei, et al.
Publicado: (2020)

Swainsonine Inhibits Invasion and the EMT Process in Esophageal Carcinoma Cells by Targeting Twist1
por: Ma, Junxun, et al.
Publicado: (2018)

Editorial: Beyond chemotherapy and immunotherapy in thoracic malignancies: Overcoming resistance by tackling new molecular pathways
por: Mountzios, Giannis, et al.
Publicado: (2022)

The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy
por: Huang, Lingling, et al.
Publicado: (2022)

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
por: Wu, Zhaozhen, et al.
Publicado: (2021)

Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer
por: Zhang, Fan, et al.
Publicado: (2020)

Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting
por: Wu, Zhaozhen, et al.
Publicado: (2021)

Rechallenge of immunotherapy beyond progression in patients with extensive-stage small-cell lung cancer
por: Li, Lingling, et al.
Publicado: (2022)

Efficacy of Recombinant Adenoviral Human p53 Gene in Treatment of Malignant Pleural or Peritoneal Effusions
por: ZHANG, Xin, et al.
Publicado: (2013)

Systemic Immune-Inflammation Index and Changes of Neutrophil-Lymphocyte Ratio as Prognostic Biomarkers for Patients With Pancreatic Cancer Treated With Immune Checkpoint Blockade
por: Shang, Jin, et al.
Publicado: (2021)

Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives
por: Gray, Steven G., et al.
Publicado: (2020)

Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib
por: Longo, Vito, et al.
Publicado: (2021)

Prognostic value of plasma D-dimer levels in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a retrospective study
por: Li, Xiaoyan, et al.
Publicado: (2022)

Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system
por: Prelaj, Arsela, et al.
Publicado: (2020)

Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond
por: Song, Chenghuan, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy in Neuroendocrine Bladder Cancer: A Case Report
por: Prelaj, Arsela, et al.
Publicado: (2016)

Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: Survival across disease and treatment subgroup analysis and review of the literature
por: Prelaj, Arsela, et al.
Publicado: (2019)

Gut mycobiome as a potential non-invasive tool in early detection of lung adenocarcinoma: a cross-sectional study
por: Liu, Qingyan, et al.
Publicado: (2023)

XRCC2 Polymorphisms and Environmental Factors Predict High Risk of Colorectal Cancer
por: Wang, Lijie, et al.
Publicado: (2018)

Efficacy and safety of pembrolizumab versus sintilimab treatment in patients with advanced squamous lung cancer: A real-world study in China
por: Yang, Wenyu, et al.
Publicado: (2023)

Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer
por: Gao, Ming, et al.
Publicado: (2023)

Deciphering pathogenic cellular module at single-cell resolution in checkpoint inhibitor-related pneumonitis
por: Cui, Pengfei, et al.
Publicado: (2023)

Is There Already a Need of Reckoning on Cancer Immunotherapy?
por: Correale, Pierpaolo, et al.
Publicado: (2021)

First-Line Treatment for Advanced SCLC: What Is Left Behind and Beyond Chemoimmunotherapy
por: Giunta, Emilio Francesco, et al.
Publicado: (2022)

Prognostic Value of the Pretreatment Lung Immune Prognostic Index in Advanced Small Cell Lung Cancer Patients Treated With First-Line PD-1/PD-L1 Inhibitors Plus Chemotherapy
por: Li, Lingling, et al.
Publicado: (2021)

Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice
por: Prelaj, Arsela, et al.
Publicado: (2019)

Multimodal treatment for local recurrent malignant gliomas: Resurgery and/or reirradiation followed by chemotherapy
por: Prelaj, Arsela, et al.
Publicado: (2019)

Cell-free DNA from cerebrospinal fluid can be used to detect the EGFR mutation status of lung adenocarcinoma patients with central nervous system metastasis
por: Liu, Yang, et al.
Publicado: (2021)

EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort
por: Prelaj, Arsela, et al.
Publicado: (2019)

Bladder Cancer Immunotherapy: BCG and Beyond
por: Askeland, Eric J., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_l4c2m3esqvj2jfcv9gsf270659